Loading clinical trials...
Loading clinical trials...
Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States
Conditions
Interventions
Adhansia XR
Concerta
Locations
35
United States
Harmonex, Inc.
Dothan, Alabama, United States
Southern California Research LLC
Beverly Hills, California, United States
CT Clinical Research
Cromwell, Connecticut, United States
Gulfcoast Clinical Research Center
Fort Myers, Florida, United States
Reliable Clinical Research, LLC
Hialeah, Florida, United States
Eastern Research. Inc.
Hialeah, Florida, United States
Start Date
July 30, 2020
Primary Completion Date
December 22, 2021
Completion Date
January 31, 2022
Last Updated
July 27, 2023
NCT06577779
NCT07379359
NCT06798337
NCT07044609
NCT05778526
NCT05257265
Lead Sponsor
Purdue Pharma LP
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions